Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies

Current licensed and commercially available prophylactic human papillomavirus (HPV) vaccines (Cervarix and quadrivalent/nine valents Gardasil) are based on major capsid protein L1 virus-like particles (VLPs) production which are expensive and type specific. Minor capsid L2-RG1 linear epitope (17-36)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Res Pharm Sci
Egile Nagusiak: Khiavi, Farhad Motavalli, Arashkia, Arash, Nasimi, Maryam, Mahdavi, Mehdi, Golkar, Majid, Roohvand, Farzin, Azadmanesh, Kayhan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Medknow Publications & Media Pvt Ltd 2017
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5566000/
https://ncbi.nlm.nih.gov/pubmed/28855937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1735-5362.212043
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak